The rate was higher in stage of CKD 3–5, and preventive medication should be used. Key Word(s): 1. low dose aspirin; 2. UGIB; 3. CKD; Presenting Author: SATOSHI SUGITA Additional Authors: MASAFUMI INOMATA, TOMONORI AKAGI, KENTARO NAKAJIMA, YOSHITAKE UEDA, MANABU TOJIGAMORI, HIDEFUMI SHIROSHITA, TSUYOSHI ETOH, NORIO SHIRAISHI, SEIGO KITANO Corresponding

Author: SATOSHI SUGITA Affiliations: Department of Gastroenterological Surgery, Oita University Faculty of Medicine Objective: Fluorouracil-based chemoradiotherapy (CRT) is regarded as a standard perioperative treatment in locally Selleckchem GPCR Compound Library advanced rectal cancer. We investigated the efficacy and safety of substituting fluorouracil with the oral prodrug TS-1. Methods: A multi-institutional (17 specialized centers), interventional phase II trial, was conducted from April 2009 to August 2011.This study is registered with UMIN-CTR, number C003396. For inclusion, patients must fulfill the following requirements before neoadjuvant CRT: (i) histologically proven rectal carcinoma; (ii) tumor located in the rectum (upper,lower); (iii) cancer

classified as T3-4, N0–3 and M0; Two cycles of neoadjuvant CRT with TS-1 (100 mg/m2 on days 1–5, 8–12, 22–26, and 29–33) is administered, and irradiation (total 45Gy/25fr, 1.8Gy/day, on days 1–5, 8–12, 15–19, 22–26, and 29–33) is performed. Total mesorectal excision with D3 lymphadenectomy is performed during the 4th and 8th week after the end of the neoadjuvant CRT. The primary endpoint is rate of complete treatment of neoadjuvant CRT. Secondary endpoints are response rate of neoadjuvant CRT, short-term clinical outcomes, INCB024360 in vitro rate of curative resection, and pathological response (grade2/3). Results: This

trial included 37 patients. A complete treatment of neoadjuvant CRT was found in 86.5% of patients (95%CI;75.5~97.5%), and an adverse event (grade 3/4) occurred in 4 patients (11.1%). Response rate (PR/CR;RECIST 1.0) was 56.8% (95%CI; 40.8~72.7%), and pathologic response rate (grade2/3) was 48.6% (95%CI; 32.5~64.8%). The median operating time was 448.5 min (IQR 340.5–505.5), 上海皓元医药股份有限公司 and median blood loss was 422.5 mL (IQR 182.5–1125). Grade 3–4 postoperative complications occurred in 6 (16.7%) patients. The most common grade 3 or 4 postoperative complication was anastomotic leakage (2 [5.6%]). Conclusion: Our prospective phase-II study demonstrated that a neoadjuvant-synchronus TS-1 + RT for locally advanced rectal cancer is feasible in terms of pathological response and adverse events. Key Word(s): 1. Rectum; 2. chemoradiotherapy; Presenting Author: VARUT LOHSIRIWAT Corresponding Author: VARUT LOHSIRIWAT Affiliations: Mahidol University Objective: To evaluate the clinical outcomes of enhanced recovery program (ERP) after colorectal surgery performed by a consultant colorectal surgeon in a University Hospital in Thailand.